Luminance conducted a tailored webinar for life science professionals in Asia and North America preparing to launch pharmaceutical products in the European Union. The event provided a focused yet thorough exploration of the essential requirements for a successful market entry, equipping attendees with actionable insights and strategic guidance. The session, led by Luminance specialists including Joanna Hanley (Head Quality Assurance), Philipp Ansorge (Head Pharmacovigilance) , Ben Stockham (Director Regulatory Affairs) and external speakers Rute Fernandes (Pharma Executive and Board Member), Thomas P. Wenk (Hoffmann & Partner AG) and Oliver Wunderle(Hoffmann & Partner AG), addressed the multifaceted challenges of launching medicinal products in Europe. Participants benefited from expert advice across key operational domains, ensuring they are well positioned for compliant, cost-effective, and commercially viable product launches throughout the region. Key topics discussed included a roadmap of EU regulatory requirements, with best practices for dossier submission, product approval, and lifecycle management. The webinar also covered proven strategies for maintaining Good Manufacturing Practice (GMP) compliance and safeguarding supply chain integrity across all EU member states.

At this year’s BioValley Annual Event, Luminance Health was represented by CEO Shayesteh Fürst-Ladani and Adrian Sutter, Associate Director Public Affairs. The event featured a high-level roundtable titled “Pharma Company Strategy in a Changing Geopolitical Environment. The panel explored how evolving geopolitical dynamics are reshaping the European pharmaceutical and start-up landscape. Discussions centred on strategic responses to these changes, with a particular focus on implications for research and development. The evening concluded with a networking apéro, fostering dialogue and collaboration across the life sciences community.

Anastasia Agapouda, Senior Manager Quality Assurance & Pharmacovigilance, and Jack Cronk, Senior Manager Medical Affairs, represented Luminance Health at the “Talk & Connect 2025” event hosted by the Basel Area. This exclusive summer gathering convened stakeholders from across the regional innovation ecosystem, including portfolio companies, strategic partners, and industry leaders, for an evening of professional exchange and celebration. The occasion served to commemorate the Basel Area’s collective achievements over the past year, reinforcing its role as a dynamic hub for life sciences and medtech collaboration.

We are proud to share that our CEO, Shayesteh Fürst-Ladani, was a featured speaker at the recent British-Swiss Chamber of Commerce (BSCC) event, “Resourceful Board Governance in the AI Transformation – Unlock the Future of Corporate Governance in the Age of AI.”

Our CEO, Shayesteh Fürst-Ladani, and Project Finance Manager, Katrin Grenda, took part in the inaugural event of the Pharma Women’s Network, a newly launched series dedicated to connecting and empowering women in the pharmaceutical and life sciences industries.

We were delighted to take part in the 8th Swiss-Chinese Life Sciences Forum, an inspiring event bringing together biotech, pharma, and investment leaders committed to shaping the future of healthcare innovation between Switzerland and China.

Our Swissmedic licence is the cornerstone of our commitment to the highest standards of Good Practice (GxP). Supported by a fully implemented Quality Management System that meets Swissmedic’s requirements, we ensure every stage is rigorously documented, controlled and subject to continuous review.

As a certified Small and Medium-sized Enterprise (SME) under European Medicines Agency criteria, we specialise in navigating non-EU clients through the EMA submission process. By combining bespoke guidance with deep EMA expertise, we empower innovators outside the EU to deliver vital therapies to European patients more swiftly and cost-effectively.

Jane Müller , Head of Legal & HR, took part in the BaseLaunch event, which centered on collaborative strategies for early-stage innovation. The program highlighted approaches to building strong partnerships in the biotech space and concluded with a networking apéro to encourage dialogue and knowledge sharing.

At Future Labs Live, Shayesteh Fürst-Ladani, CEO, and Jack Cronk, Senior Manager Medical Affairs, attended the keynote panel titled Transforming Research: Can We Make Open Science a Reality?, contributing to conversations on transparency, collaboration, and open innovation in AI-driven research.

Sabrina Urwyler, Associate Director Regulatory Affairs & Project Management, attended the Life Science Zurich Impact Conference on “Precision Medicine and AI Innovations,” where experts from academia, healthcare, and research gathered to explore the transformative role of artificial intelligence in medical treatment. Discussions addressed both the potential and the challenges of these technologies in advancing translational medicine.

Luminance Health GmbH, a boutique consultancy serving the life sciences and healthcare spectrum, is pleased to announce the formation of its Advisory Board. This distinguished group of global leaders will provide strategic counsel and operational insight, further strengthening Luminance Health’s mission to support pharmaceutical, medtech, and digital health organizations in navigating regulatory complexity, driving innovation, and accelerating the successful delivery of transformative solutions to market.

Basel, Switzerland, 6 May 2025 - Luminance Health made a strong impact at Swiss Biotech Day 2025, one of Europe’s premier life sciences events, held in Basel on 5-6 May.

Basel, Switzerland, 8 April 2025 - On a beautiful spring evening, the Luminance Health team gathered with friends, partners, and esteemed guests to celebrate the expansion of services of Luminance Health at the Spring Apéro.

Luminance Health, a boutique consultancy, is proud to launch its comprehensive range of tailored services designed to help Life Science organizations to succeed in Switzerland, EU and global markets.